Hormones Radiology Trials 
pharmaphorum
JULY 17, 2024
Bayer has the result it was hoping for in the phase 3 ARANOTE trial of Nubeqa in metastatic, hormone-sensitive prostate cancer (mHSPC), a key part of its plan to build the drug into a €3 billion-a-year blockbuster.ARANOTE compared Nubeqa (darolutamide) to placebo given with standard androgen deprivation therapy (ADT) and showed a significant improvement (..)
Worldwide Clinical Trials
JULY 8, 2024
Hormonal Status : A body’s hormones, such as levels of reproductive hormones and thyroid function, can impact tissue responses to radiation therapy. International Commission on Radiological Protection (ICRP) The ICRP provides recommendations and guidance on radiation protection standards for occupational and public exposure.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Delveinsight
DECEMBER 29, 2020
Relugolix is a once-daily, oral gonadotropin-release hormone (GnRH) receptor antagonist. Audentes Therapeutics’ ASPIRO Trial Free to Proceed. The ASPIRO trial is a two-part, open-label ascending dose study, and is examining the safety and preliminary efficacy of AT132 in children with XLMTM younger than five years old.
Delveinsight
SEPTEMBER 27, 2021
It can be due to the previous existence of brain damage signs (psychomotor retardation, neurologic signs, radiologic signs, or other types of seizures) or on the basis of etiology that is characterized by a lack of previous signs of brain damage. There are many different causes of epileptic spasms.
The Pharma Data
FEBRUARY 21, 2022
Our leadership in cardiology, radiology and women’s health is recognized worldwide, and we are expanding our presence in oncology, working tirelessly to bring forward new approaches that can change the treatment paradigm for patients,” said Stefan Oelrich, Member of the Board of Management, Bayer AG and President of Bayer’s Pharmaceuticals Division.
The Pharma Data
AUGUST 15, 2021
The approval is based on results from the open-label Study 004 trial (N=61), where the major efficacy endpoint was overall response rate (ORR) in patients with VHL-associated RCC. Advise patients of these risks and the need for effective non-hormonal contraception. WELIREG can render some hormonal contraceptives ineffective.
The Pharma Data
MARCH 17, 2021
The data builds on the primary outcome analysis of the positive Phase 3 monarchE trial that previously showed Verzenio, in combination with ET, decreased the risk of breast cancer recurrence by 28.7 The monarchE trial is ongoing and patients will continue to be followed to assess safety, PROs and other endpoints. had fatal outcomes.
Expert insights. Personalized for you.
80 
Let's personalize your content